MacroGenics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Maryland, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
9704 Medical Center Dr, Rockville, Maryl...Phone Number
(301) 251-5172Website
www.macrogenics.comRevenue
$149.5 MillionStock Symbol
MGNXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About MacroGenics
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The combination of MacroGenics' technology platforms and protein engineering has allowed the Company to generate product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.Explore more
MacroGenics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MacroGenics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at MacroGenics
MacroGenics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MacroGenics has new funding data
Website visits: Recent activity has been detected on your website
Check out if MacroGenics is spiking on competitors!
Click to see if MacroGenics had a recent Job posting/layoffs
Check if MacroGenics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MacroGenics launches new products
Earning: See what the market has to say on MacroGenics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MacroGenics
Compare insights from companies similar to MacroGenics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
MacroGenics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MacroGenics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MacroGenics.
MacroGenics financials insights
Gather financial insights about MacroGenics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series D
$25M
2010
Grant
$9.8M
2013
Stock Offering
$83.8M
2014
Stock Offering
$76.7M
2015
Stock Offering
$141M
2017
Stock Offering
$23.6M
2018
Stock Offering
$110M
MacroGenics Tech Stack
A closer look at the technologies used by MacroGenics
See more technologies
Most Recent Scoops
Open Position
Partnership
MacroGenics has a multi-program collaboration with Gilead encompassing three active programs including a CD123-targeting bispecific for AML, MDS, and other CD123-positive hematologic malignancies with approximately $1.7 billion in potential milestones and approximately $100 million already collected. Gilead holds options to assume development responsibility for each program at predefined decision points.
Partnership
Partnership
MacroGenics has an amended ZYNYZ royalty agreement with Incyte, under which Incyte reported Q1 sales of approximately $40 million a tenfold increase year-over-year following additional approvals for frontline anal cancer in the US, Europe, and Japan.
Contracts
Pain Point
MacroGenics has experienced a Grade 4 hematology related adverse events including thrombocytopenia and neutropenia one of which resulted in a fatality. The company noted that these toxicities may be partially attributable to the platinum-resistant patient population studied, as platinum therapy can deplete bone marrow.
Clinical Operations
Project
Acquisitions, Manufacturing Operations
MacroGenics News & Media
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and highlighted its recent corporate progress.MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to BoraMacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MacroGenics
Sign Up For FreeTo access detailed company insights
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The combination of MacroGenics' technology platforms and protein engineering has allowed the Company to generate product candidates and enter into several strategic collaborat... Read More
